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Abstract
Current vaccines used for the prevention of brucellosis are ineffective in inducing protective immunity in animals that are
chronically infected with Brucella abortus, such as elk. Using a gene discovery approach, in vivo-induced antigen technology
(IVIAT) on B. abortus, we previously identified ten loci that encode products up-regulated during infection in elk and
consequently may play a role in virulence. In our present study, five of the loci (D15, 0187, VirJ, Mdh, AfuA) were selected for
further characterization and compared with three additional antigens with virulence potential (Hia, PrpA, MltA). All eight
genes were PCR-amplified from B. abortus and cloned into E. coli. The recombinant products were then expressed, purified,
adjuvanted, and delivered subcutaneously to BALB/c mice. After primary immunization and two boosts, mice were
challenged i.p. with 5610
4 CFU of B. abortus strain 19. Spleens from challenged animals were harvested and bacterial loads
determined by colony count at various time points. While vaccination with four of the eight individual proteins appeared to
have some effect on clearance kinetics, mice vaccinated with recombinant Mdh displayed the most significant reduction in
bacterial colonization. Furthermore, mice immunized with Mdh maintained higher levels of IFN-c in spleens compared to
other treatment groups. Collectively, our in vivo data gathered from the S19 murine colonization model suggest that
vaccination with at least three of the IVIAT antigens conferred an enhanced ability of the host to respond to infection,
reinforcing the utility of this methodology for the identification of potential vaccine candidates against brucellosis.
Mechanisms for immunity to one protein, Mdh, require further in vitro exploration and evaluation against wild-type B.
abortus challenge in mice, as well as other hosts. Additional studies are being undertaken to clarify the role of Mdh and
other IVI antigens in B. abortus virulence and induction of protective immunity.
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Introduction
Brucellosis continues to be problematic to the agriculture
industry world-wide, including the U.S. Furthermore, several
Brucella spp. have been classed as category B threat list agents with
the potential for use as bioterrorism weapons. Efforts to develop an
effective, stable, and non-reactogenic vaccine against brucellosis
have been ongoing in several laboratories, and the use of a live,
attenuated platform has become the established benchmark
through the use of the B. abortus rough strain RB51 [1]. Although
moderate efficacy against Brucella-induced fetal abortions in
domestic livestock (cattle) has been reported [2], acceptable levels
of protection following immunization with RB51 has yet to be
demonstrated in wildlife such as elk [3,4,5,6], and in the case of
bison, results have been conflicting in terms of the vaccine’s
reactogenicity [7,8,9,10,11]. The exact nature of the attenuation
of RB51 is also unclear, although it’s rough LPS phenotype is due
to at least one lesion in O-side chain biosynthesis loci [1]. A more
systematic approach to the induction of active protective immunity
against brucellosis has been undertaken by some laboratories
through the development of subunit vaccines [12,13,14,15,16,17].
To date, the degree of success in protecting with such vaccines
depends on the ability of the candidate to drive immunity towards
a Th1-type response, emphasizing the need to identify and
characterize Brucella antigens which present T-cell epitopes to the
host [18]. Despite the efforts to identify components for a next-
generation subunit vaccine, formulations using recombinant
Brucella antigens have not been thoroughly assessed for immuno-
genicity/efficacy. The discovery of additional Brucella virulence
factors thus may facilitate the development of a more efficacious,
less reactogenic, acellular product that may either be used as a
stand-alone vaccine or used to augment primary immunization
with the existing live, attenuated platform. As an example of the
latter strategy, enhanced efficacy in the mouse model has been
reported by over-expressing Brucella superoxide dismutase (SOD)
in RB51 or complementing the strain’s rough LPS phenotype with
the O-side chain biosynthesis locus, wboA [19].
We previously applied the gene discovery methodology, known
as in vivo-induced antigen technology (IVIAT), to identify B.
abortus virulence genes up-regulated during infection in elk (Cervis
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17425elaphus), and as a result have identified ten loci with gene products
potentially important to survival of the pathogen in this host [20].
Furthermore, the conserved nature of most of these gene products
has led us to extend our hypothesis - that they also may be
requisite virulence effectors in other Brucella susceptible hosts. As a
preliminary approach to confirming our hypothesis, we have
selected five of these in vivo-induced (IVI) products for further
characterization in a surrogate murine model for B. abortus
colonization: a conserved outer membrane protein, D15; a
gluconeogenic enzyme, malate dehydrogenase (Mdh); a periplas-
mic component of an ABC transport system, AfuA; a component
of the Type-IV secretion system (T4SS) VirJ; and a lipoprotein of
unknown function BAB1_0187 (referred to as 0187). We also
targeted three additional conserved gene products based on high
amino acid sequence similarity with antigens identified through
Yersinia pestis IVIAT and previous reports of a role in Brucella
pathogenesis [21,22]: proline epimerase (PrpA), an auto-secreting
(Type-V) surface antigen, Hia, and a soluble lytic transglycosylase,
MltE.
Results
S19 Infection Kinetics
To establish the colonization kinetics of B. abortus S19 in BALB/
c mice in our laboratory, thirty naive animals were infected with
S19 at 5610
4 CFU and five animals sacrificed at 7, 14, 21, 28, 42,
and 70 days post-infection. Bacterial loads in spleens peaked in two
weeks at 8610
7 CFU before gradually declining to 6610
3 CFU in
6 weeks. At 10 weeks post infection, organisms were still able to be
cultured from spleens in 60% of the animals. Also, splenomegaly
was observed in S19-infected mice, peaking between 14 and 21
days post-infection, and declining by day 28 (data not shown).
S19 challenge after vaccination with recombinant IVI
products
In the first experiment, thirty mice were vaccinated with
purified Mdh, MltE, or adjuvant-only. After hyper-immunization
with the recombinant proteins, the sera were assessed for antibody.
End-point titers from mice immunized with the recombinant
protein ranged from a 1:1000 to 1:5000. Serum from mice
receiving alhydrogel alone was non-reactive against any of the
proteins.
After challenge, bacterial loads in the spleens were determined
at 7, 14, 21, and 28 days post-infection. As shown in Table 1, mice
vaccinated with Mdh showed a markedly significant decrease in
bacterial colonization at 14 dpi, providing 2.75 log units of
clearance and 2 log units of clearance at 21 days post-infection
compared to adjuvant-only treated animals (p,0.001). Bacterial
loads measured in MltE-immunized mice were no different than
the adjuvant-only controls (not shown). Mdh-immunized animals
also displayed extended splenomegaly which remained elevated
relative to the adjuvant-only animals at 28 days post-infection
(data not shown). By 42 days, the Mdh-immunized animals had
completely cleared the infection, while S19 was still cultured from
spleens of the adjuvant-only mice at the same time point (data not
shown).
In a second experiment, fifteen mice each received alhydrogel
only, AfuA, Hia or D15 recombinant proteins adsorbed to the
adjuvant. Mice were primed and boosted twice, and serum was
collected to assay for antibody titers. Reactivity of the immune sera
to all three antigens was detectable out to 1:1000 for Hia and
1:5000 for D15 and AfuA (comparable to that of Mdh immunized
mice). The animals were challenged as before and bacterial loads
in the spleens assessed at 14, 21, and 28 days post-infection. As
shown in Table 2, in contrast to Mdh, there was no significant
difference at two weeks between the adjuvant-only and antigen-
immunized animal groups, however at three weeks post-infection
all three experimental groups differed significantly from the
adjuvant-only group with D15 showing the most pronounced
effect of 1.41 log units of clearance (p,0.001). As observed with
Mdh-immunized animals, splenomegaly remained consistently
elevated in all test groups at 28 days post- infection relative to the
adjuvant-only control animals (data not shown).
A third iteration was then conducted to evaluate VirJ, 0187, and
PrpA. Following the same methods as above, antibody titers were
determined to be .1:5000 (VirJ, PrpA and 0187). Mice were
challenged with S19 and splenic colony counts were performed as
described previously at 14 and 21 days post-infection. No
significant difference was found between adjuvant-only animals
and those receiving any of the three antigens (data not shown),
although all immune animals displayed some degree of spleno-
megaly.
Mouse cytokine response to challenge with S19
Levels of IL-12p70, IL-4 and IFN-c in the splenic homogenates
were quantified from the five selected animal groups immunized
with antigens which had an effect on bacterial load and/or
clearance rate. No detectable IL-12p70 or IL-4 groups immunized
with AfuA, Hia, D15, or adjuvant alone was observed. IL-4 was,
however, detected in Mdh-vaccinated mice, although at low levels
(data not shown).
IFN-c was next assessed in vaccinated mice after challenge. As
shown in Figure 1, at all sampling times, mice vaccinated with
Mdh showed significantly higher levels of this cytokine (p,0.05),
compared to the mice receiving AfuA, D15, or alhydrogel alone.
By 21 and 28 days post-infection, IFN-c levels among all groups
had declined with the exception of the Mdh immune group, in
which IFN-c remained significantly elevated (p,0.05; Figure 1).
In Vivo assessment of IVI gene up-regulation during S19
infection in mice
‘‘Short-unique’’ regions of selected IVI genes identified through
IVIAT from elk infected with wild-type B. abortus were selected for
construction of RT-PCR primers. Ten BALB/c mice were
subsequently infected with S19, five of which were splenectomised
at 24 and 48 hours post-infection, and bacterial mRNA isolated.
Additionally, S19 was grown to mid-log phase in vitro and mRNA
Table 1. Reduction of bacterial load and more rapid
clearance in a murine colonization model by immunization
with recombinant B. abortus Mdh.
Time, Post-
infection
(days)
Adjuvant
Only Mdh p value
Log
reduction
0 ----
7 2.51610
6
(+/2 3.34610
5)
8.05610
5
(+/2 5.62610
5)
,0.05 0.55
14 9.94610
7
(+/2 2.17610
7)
2.43610
5
(+/2 1.12610
5)
,0.001 2.75
21 2.64610
6
(+/2 8.57610
5)
3.73610
4
(+/2 2.08610
4)
,0.001 2.09
28 1.386105
(+/2 8.37610
4)
1.29610
4
(+/2 1.00610
4)
,0.05 1.09
doi:10.1371/journal.pone.0017425.t001
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up-regulation during both 24 and 48 hours post-infection of afuA,
mdh, and 0187 (Figure 2). In contrast, D15 mRNA was not
detected in either the in vitro or in vivo samples, even after
performing several different nested RT-PCR reactions (data not
shown). While, prpA and mltE were not examined, Hia-encoding
transcript was expressed at equivalent levels in vitro and during
infection (data not shown).
Discussion
The use of a murine model for the characterization of B. abortus
IVI proteins as potential protective antigens is likely not the
optimal animal model for simulation of the disease state in the
natural host species. Consequently, behavior of recombinant
antigens and/or mutants may be different in mice than the target
species. Despite this drawback, some mouse strains have been
shown to be highly sensitive to the pathogen, and have been used
to study B. abortus pathogenesis and evaluate vaccine candidates for
the past two decades [23,24,25,26,27,28]. Furthermore, studies
with S19 in pregnant BALB/c mice reported an identical
pathology, placentitis and septic fetal death, as with wild-type B.
abortus infection, further supporting the applicability of this model
to the simulation of disease in other host species [28,29]. The
benefit of using S19 instead of wild-type B. abortus is reduced cost
and safety, since BSL-3 small animal containment facilities are not
required.
Vaccination with purified B. abortus Mdh resulted in significantly
reduced colonization and more rapid clearance of S19 in the
BALB/c mouse. Interestingly, Mdh was the only recombinant
protein of the five antigens examined which facilitated some level
of clearance that elicited a significant IFN-c response, a cytokine
critical for the activation of macrophages and a requisite for
controlling Brucella infections [30]. It is therefore likely that
prolonged elevated levels of IFN-c in mice vaccinated with Mdh
contribute to the reduction in the colonization by S19 in these
immune animals. The nature of Mdh-induced immune-mediated
enhanced clearance is unclear at present, however, it is possible
that an auxiliary virulence function of the enzyme may be
neutralized by a robust immune response directed toward it. The
presence of IL-4 and absence of IL-12 also suggest that mice
vaccinated with Mdh induce a Th2-biased response leading to
Table 2. Reduction of bacterial load in a murine colonization model by immunization with recombinant B. abortus AfuA, D15, or
Hia.
Time (days)
Post-infection
Adjuvant
Only AfuA D15 Hia p value
Log
reduction
0 ----
7 2.51610
6 ND ND ND
(+/2 3.34610
5)
14 9.94610
7 2.89610
7 4.40610
7 1.88610
7
(+/2 2.17610
7)( +/2 1.78610
7)( +/2 2.23610
7)( +/2 7.02610
6)
21 2.64610
6 6.53610
4 1.23610
5 4.20610
4 ,0.001 1.41
(+/2 8.57610
5)( +/2 5.38610
4)( +/2 8.05610
4)( +/2 2.81610
4) (D15)
28 1.38610
5 1.59610
4 1.50610
4 2.89610
4 ,0.05 1.91
(+/2 8.37610
4)( +/2 9.31610
3)( +/2 9.08610
3)( +/2 1.27610
4) (Hia)
doi:10.1371/journal.pone.0017425.t002
Figure 1. IFN-c response in Mdh-immunized BALB/c mice after S19 challenge. Spleen homogenates from the five mice from each time
point (7,14,21 and 28 dpi) sacrificed during the challenge studies were evaluated for IFN-c production.
doi:10.1371/journal.pone.0017425.g001
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putative T- and B-cell epitopes across the amino acid sequence of
the protein revealed only the latter (data not shown). This
hypothesis may seem contrary to the traditional notion that only a
Th1-biased response can reduce intracellular bacterial load in the
Brucella-infected host. Indeed, previous experiments with other
facultative intracellular pathogens such as Yersinia pestis have
demonstrated that antibody alone can confer protection against
challenge [31]. In the case of B. abortus, an ‘‘optimized’’ Th2
response might also contribute significantly to clearing infection.
Although, immunity to AfuA and D15 failed to elicit more rapid
clearance of S19, bacterial loads were significantly reduced in
animals immunized with either of these two proteins. In contrast to
AfuA and Mdh, D15 expression was not evident early in S19
colonization, thus D15 may be relevant at a later stage of infection
in the mouse. Curiously, in our previous study [20], we failed to
detect antibody to Mdh and D15 in S19-immunized elk, indicating
that both proteins may be regulated differently in cervids.
Hia was not identified as an IVI gene in our initial study [20],
and consistent with this finding, was subsequently was found to be
constitutively expressed based on our mRNA analysis (data not
shown). Our selection of this gene product was based on similar
homology to Y. pestis protein and previous reports in the literature
of involvement as a virulence factor [32]. This type-V auto-
secreted antigen, induced a greater level of extended splenomegaly
compared to the other recombinant proteins, including Mdh.
However, the increased inflammation did not correlate with
heightened production of IFN-c (data not shown). This observa-
tion suggests that perhaps immunity to Hia increases the
inflammatory response during infection by mechanisms not related
to IFN-c, such as TNF-a or IL-1. Although immunization with
Hia reduced bacterial load in our model comparable to D15 and
AfuA, it failed to induce more rapid clearance.
As with MltE, 0187, PrpA, and VirJ failed to reduce bacterial
load and/or alter clearance kinetics compared to adjuvant-only
controls. 0187 is a putative lipoprotein that shares significant
homology with the well characterized BA14K protein. Previous
studies have demonstrated that BA14K was able to induce a Th1
response and induce IL-12 secretion [33]. We were unable to
express 0187 from B. abortus as a full length protein but were able
to stably express a truncated form shortened by 27 amino acids
from the n-terminus (data not shown). It is possible that this
truncation could have resulted in conformation changes leading to
an inability to induce clearance immunity.
The proline epimerase, PrpA, was described as a B-cell
polyclonal activator and inducer of IL-10 [22], suggesting that
immunity to this protein may promote clearance in our model
based on the pivotal role IL-10 plays in Brucella pathogenesis
[30,34]. Mice immunized with PrpA during early infection
actually had splenic counts higher than animals immunized with
adjuvant alone. It is possible that a secondary exposure to PrpA
results in host immune dysregulation early during the course of
infection.
The data from our previous study strongly suggested that the
Type-IV secretion system (T4SS) accessory protein, VirJ, is up-
regulated during wild type B. abortus infection in elk. Animals
immunized with S19 however did not generate a humoral
response to the protein (unpublished data), which suggests a
difference in the way this secreton is utilized by S19 in cervids.
Consistent with this finding, in the S19 murine colonization
model, VirJ appeared to be slightly down-regulated at least during
early stages of infection. A BLAST analysis upstream and
downstream of the VirJ-encoding locus revealed no differences
between S19, 2308 or 9-941 (Wyoming strain) DNA sequences,
suggesting the involvement of a distal regulatory element(s) in
controlling expression of this protein in S19. The function of VirJ,
as assessed in other pathogens, is suspected to be as a periplasmic
chaperone responsible for assisting substrates in associating with a
‘‘pusher’’ pilus before translocation through the T4SS, typically
thought to be required for full virulence in this pathogen [35]. In
this regard, we intend to re-evaluate VirJ in a B. abortus 2308
challenge model.
Data from our model system is in agreement with that
previously published for S19 colonization kinetics in BALB/c
mice [23]. Our vaccination efforts with a single recombinant
protein, Mdh, coincide with previously reported data on mice
vaccinated with RB51 in terms of the subsequent cytokine
responses post-challenge [36]. IFN-c levels peak between 6 and
7 days then begin to slowly decline, albeit remaining sustained for
weeks [36]. RB51 vaccinates also lack significant production IL-
12p70 or high levels of IL-4 upon challenge. [36]. This
observation could be peculiar to BALB/c mice, which tend to
Figure 2. IVI genes upregulated in vivo during S19 infection. Average Fold change of bacterial mRNA isolated from five mice infected with
S19 at each time point compared to in vitro-grown B. abortus S19.
doi:10.1371/journal.pone.0017425.g002
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predicted, our S19 data shows that a pro-inflammatory response
is suppressed in naı ¨ve animals and behaves similarly to strain 2308
in this respect [30]. This observation suggests that a shift in
cytokine production levels could be important in providing a more
efficacious immune response to brucellosis.
Taken together, these data suggest the potential for use of the
gluconeogenic enzyme, malate dehydrogenase, as a recombinant
subunit vaccine candidate for brucellosis. AfuA, D15, and/or Hia
may also represent promising subunit vaccine candidates when
used together and/or in combination with Mdh. In this regard, we
plan to evaluate such antigen cocktails in the near future, using
wild type field isolates of B. abortus in mice and other host species.
Methods
Bacterial strains and growth conditions
Brucella abortus S19, was kindly provided by the Colorado Serum
Company (Denver, CO), and was used exclusively for this study in
the mouse colonization/infection model. Brain-heart infusion broth
cultures were typically grown overnight at 37uC, serially diluted
after three washes in sterile PBS, followed by plating to determine a
viable cell count correlate with optical density at 600 nm.
In vivo gene expression, RNA extraction, and RT-PCR
Ten BALB/c mice were infected with 1610
7 cfu of B. abortus
S19 i.p. Mice were splenectomized and tissues stored in
RNAlater
TM (Ambion, Austin, TX). Tissues were homogenized
and RNA isolated with the RiboPure-Bacteria
TM Kit (Ambion,
Austin, TX). Isolated RNA was transcribed to cDNA using
RETROscript
TM (Ambion, Austin, TX) and cDNA targets
amplified by PfuTurbo
TM DNA Polymerase (Stratagene, La Jolla,
CA) in a one-step reaction. Amplification of a segment of the 16S
subunit of B. abortus S19 was used as a positive control; negative
controls were included for each gene and contained all the
reaction components except reverse transcriptase. In addition a
negative control was employed which lacked RNA template to
confirm the absence of DNA contamination in the reaction.
Concentration of PCR product in gel bands was assessed using
Quantity One
TM 4.6 software (Bio-Rad, Hercules, CA).
Plasmid construction, recombinant protein expression,
and purification
Selected IVI genes were amplified in their entirety from the B.
abortus RB51 genome by PCR, using PfuUltra Master Mix
(Stratagene, La Jolla, CA), inserted into the pET-46 Ek/LIC
TM
system (EMD Biosciences, La Jolla, CA), and transformed into E.
coli NovaBlue cells (EMD Biosciences, La Jolla, CA). The
recombinant plasmid constructs were then purified and the insert
sequence confirmed by PCR and sequencing. The recombinant
plasmids were re-transformed into E. coli Rosetta-2[DE3] cells
(EMD Biosciences, La Jolla, CA) and induced to express under
0.5 mM IPTG at 30uC. Verification of expression of recombinant
products was performed by total crude protein resolution on SDS-
PAGE followed by Western blot analysis using a His-tagged
Monoclonal antibody (EMD Biosciences, La Jolla, CA). Ten mls
of 0.5 mM IPTG-induced cultures of recombinant E. coli strains
were treated with BugBuster HT (EMD Biosciences, La Jolla, CA)
and soluble (AfuA, Mdh, MltE, 0187) and insoluble (D15, VirJ,
Hia) fractions containing recombinant histidine-tagged fusion
proteins purified by the HisMag
TM Purification Kit (EMD
Biosciences, La Jolla, CA). Insoluble fractions containing D15,
VirJ, and Hia were purified under 8 M Urea, followed by dialysis
against PBS. The proteins were run on a SDS-PAGE gel to
confirm purity and quantified by spectral absorption at 280 nm
and BCA Lowry (Pierce Chemical).
Subunit vaccine preparation
Purified proteins were mixed with a 1:7 dilution of aluminum
hydroxide adjuvant (Alhydrogel
TM; Superfos, Denmark) in PBS
and adsorbed overnight at 4uC at a concentration of 150 mg/mL.
Animal studies
All animals utilized in this study were cared for according to
strict adherence to the Policies and Regulations established by the
US Public Health Service ‘‘Humane Care and Use of Laboratory
Animals’’ and an approved animal protocol from the University of
Wyoming Institutional Animal Care and Use Committee
(IACUC) (DHHS Assurance #A3216-1).
Ten to 30 six-week old, female BALB/c mice received 30 mgo f
recombinant protein subcutaneously in 200 mL of adjuvant at one
site. Additional control mice were treated with adjuvant only in the
same manner. Immunization regimen consisted of a prime and two
boosts, 21 days apart. Retro-orbital bleeds were performed to assess
antibody titers by Western blot. Animals were challenged i.p. with
5610
4 organisms of B. abortus S19 at 14 days after the second boost.
Five mice from each group were sacrificed at specific time points.
Spleens were removed, weighed, homogenized, used to determine
whole organ bacterial load following serial dilution of the
homogenates in 1X Sterile PBS and plating on blood agar. The
remaining homogenateswerestored at 240uC forcytokineanalysis.
Cytokine analysis
Supernatants from spleen homogenates were used in Quanti-
Kine
TM ELISA Assays (R & D Systems, Minneapolis, MN) to
quantify IL-12p70, IL-4, and IFN-c cytokine levels in the spleen.
Statistics
All statistical analysis was performed with the software package
SAS 9.1 Enterprise
TM (SAS Corporation, Cary, NC). ANOVA
was used to compare means of groups and Least Significant
Difference (LSD) was used to determine mean separations between
the groups. a=0.05; p values are listed in text.
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